Abstract
responses, progression free survival, adverse events and quality of life functions. Results: Out of the 27 patients 13 were males and 14 females. Both arms were well matched for disease stage, performance status and age. In the Lapatinib arm, 8/13 patients (61.5%) had partial response and 2/13 patients (15.3%) had stable disease. 3/13 patients (23%) had progressive disease. In chemotherapy-only arm 5/14 patients had partial response (36%) while 3/14 patients (21%) had stable disease. 6/14 patients (43%) had progressive disease. The partial response rates were significantly more in Lapatinib arm (p = 0.03) while partial response plus stable disease were not significantly different between two arms (p = 0.3). The median disease free survival was significantly more in Lapatinib arm than the chemotherapy-only arm (7.8 months vs 5.5 months) (p = 0.02). Median overall survival was not reached in either arm. The treatment was well tolerated in both the arms with no major skin rash and cardiotoxicity seen with Lapatinib Conclusions: There is a good rationale to use dual blockade of Her2 and EGFR along with chemotherapy in NSCLC. As found in this study, it may translate into better tumor responses and even better survival especially in never or seldom smokers. This hypothesis needs to be tested in large multicenter trials.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
